SCHEMBL667280

SCHEMBL667280

CC(C)(C)C(O)CC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PGD P52209 2/20 0.50
SLC22A6 Q4U2R8 1/20 0.48
TSHR P16473 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 1/20 0.41
GABRR1 P24046 2/20 0.40
LMNA P02545 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
HMGCR P04035 1/20 0.38
CHRM1 P11229 1/20 0.38
TBXA2R P21731 1/20 0.38
ADRA1A P35348 1/20 0.38
GPR84 Q9NQS5 4/20 0.37
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6803525 1.00 PGD (0.50) PGDSLC22A6TSHRSMN1; SMN2MAPT
SCHEMBL6805671 1.00 PGD (0.50) PGDSLC22A6TSHRSMN1; SMN2MAPT
Ammonia Solution, Strong SCHEMBL27881579 0.97 PGD (0.48) PGDSLC22A6TSHRSMN1; SMN2MAPT
SCHEMBL6448085 0.83 ALDH1A1 (0.46) PGDTSHRTDP1CYP2C19
SCHEMBL6448088 0.83 ALDH1A1 (0.46) PGDTSHRTDP1CYP2C19
SCHEMBL14962078 0.80 SLC22A6 (0.52) PGDSLC22A6TSHRSMN1; SMN2MAPT
SCHEMBL3650683 0.79 PGD (0.47) PGDSLC22A6TSHRSMN1; SMN2MAPT
SCHEMBL25660449 0.79 PGD (0.47) PGDSLC22A6SMN1; SMN2MAPTGABRR1
SCHEMBL6462796 0.77 PGD (0.46) PGDSLC22A6SMN1; SMN2MAPTGABRR1
SCHEMBL2467277 0.76 TSHR (0.43) PGDTSHRLMNATDP1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630424-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS Third Harmonic Bio, Inc. (US) 2025-10-15 EP disclosed
EP-4592332-A1 METHOD FOR PREPARING ALKYL POLY(3-HYDROXYPROPIONATE), ALKYL POLY(3-HYDROXYPROPIONATE), AND COMPOSITION COMPRISING SAME LG CHEM, LTD. (KR) 2025-07-30 EP disclosed
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-02-20 US disclosed
CN-113728028-B Compatible blends of terephthalate polyols and hydrocarbon blowing agents 陶氏环球技术有限责任公司 2024-09-27 CN disclosed
CN-118434786-A Imide-containing polyols, methods for preparing imide-containing polyols, and methods of using imide polyols 陶氏环球技术有限责任公司 2024-08-02 CN disclosed
US-20240254119-A1 COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS Calixis Inc. 2024-08-01 US disclosed
WO-2024124002-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS THIRD HARMONIC BIO, INC. (US) 2024-06-13 WO disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 US disclosed
WO-2023092817-A1 ADDITIVE FOR 193 NM DRY PHOTORESIST AND PREPARATION METHOD FOR AND APPLICATION OF ADDITIVE 上海新阳半导体材料股份有限公司 2023-06-01 WO disclosed
US-11629134-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2023-04-18 US disclosed
US-20120045398-A1 Method For The Manufacture Of Nanoparticle Complexes And Triblock Polymer Ligands And Products Thereof CENTRUM FUER ANGEWANDTE NANOTECHNOLOGIE GMBH (DE) 2012-02-23 US disclosed
EP-2403920-A2 A METHOD FOR THE MANUFACTURE OF NANOPARTICLE COMPLEXES AND TRIBLOCK POLYMER LIGANDS AND PRODUCTS THEREOF Centrum für Angewandte Nanotechnologie (CAN) GmbH (DE) 2012-01-11 EP disclosed
US-20110105654-A1 Method for Producing a Compound with at Least One at Least Monosubstituted Amino Group BOREALIS AGROLINZ MELAMINE GMBH (AT) 2011-05-05 US disclosed
WO-2010100118-A2 A METHOD FOR THE MANUFACTURE OF NANOPARTICLE COMPLEXES AND TRIBLOCK POLYMER LIGANDS AND PRODUCTS THEREOF CENTRUM FÜR ANGEWANDTE NANOTECHNOLOGIE (CAN) GMBH (DE) 2010-09-10 WO disclosed
US-20080051326-A1 Antiinfective Lipopeptides CUBIST PHARMACEUTICALS, INC. 2008-02-28 US disclosed
US-6903233-B2 Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester TAKASAGO INTERNATIONAL CORPORATION (JP) 2005-06-07 US disclosed
US-20030225301-A1 Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester TAKASAGO INTERNATIONAL CORPORATION (JP) 2003-12-04 US disclosed
EP-1344763-A1 Process for producing optically active 3-halogenocarboxylic acid esters and 3-azide-carboxylic acid esters Takasago International Corporation (JP) 2003-09-17 EP disclosed
US-4725620-A 2H-pyran-2,6-(3H)-dione derivatives with anti-allergic activity ALLERGAN, INC. (US) 1988-02-16 US disclosed
US-4288335-A REACTING ESTER WITH PHOSPHORUS SULFIDE, METAL OXIDE OROGIL (FR) 1981-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225301-A1 Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester HDHD5, APEH, AOC3 PGD 919/4885SLC22A6 1264/4885TSHR 302/4885
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 PGD 4547/4885SLC22A6 2628/4885TSHR 791/4885
US-11629134-B2 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 PGD 4547/4885SLC22A6 2628/4885TSHR 791/4885
US-20240254119-A1 COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS KIT, AURKC, PRKCE PGD 3089/4885SLC22A6 3622/4885TSHR 4660/4885
US-20080051326-A1 Antiinfective Lipopeptides VIP, NGLY1, PREP PGD 2705/4885SLC22A6 3518/4885TSHR 4050/4885
US-20110105654-A1 Method for Producing a Compound with at Least One at Least Monosubstituted Amino Group GNMT, PAM, SMOX PGD 215/4885SLC22A6 3385/4885TSHR 1761/4885
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 PGD 4547/4885SLC22A6 2628/4885TSHR 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.